Есть нота FDA от 18 мая https://aidsinfo.nih.gov/news/2094/statement-on-potential-safety-signal-in-infants-born-to-women-taking-dolutegravir
Расхождения на уровне статпогрешности,к тому же на специфическом контингенте. Практика применения в Европе и США этого не подтверждает. Будет примерно такая же история, как и со Стокрином. Беременейте на DTG смело, вобщем.The concern stems from a preliminary unscheduled analysis of an ongoing NIH-funded birth surveillance study in Botswana, which has reported an increased risk of neural tube defects among infants of women who became pregnant while taking DTG-based regimens. The study reported 4 cases of neural tube defects out of 426 infants born to women who became pregnant while taking DTG-based regimens. This rate of approximately 0.9% compares to a 0.1% risk of neural tube defects among infants born to women taking non-DTG-based regimens at the time of conception.